Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women
Rasch A, Hodek J-M, Runge C, Greiner W (2009)
PHARMACOECONOMICS 27(8): 693-704.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Rasch, Andrej;
Hodek, Jan-MarcUniBi;
Runge, Claus;
Greiner, WolfgangUniBi
Einrichtung
Abstract / Bemerkung
Background: Menopause is a natural physiological event that usually begins in women between the ages of 48 and 55 years. In many cases, this event is associated with unpleasant somatic-vegetative, urogenital or psychological symptoms. Objective: To test the health and social demographic factors (especially household income level) that influence willingness to pay (WTP) for a new hormone-free treatment in women of menopausal age. Methods: 1365 women between the ages of 45 and 73 years were surveyed about their health and WTP for the new treatment. WTP was evaluated with a closed-ended binary questionnaire (four groups with different levels of co-payment between is an element of 15 and is an element of 60), using the contingent valuation method. The average WTP was calculated according to the area under the demand function. Factors contributing to payment readiness were examined by means of binary logistic regression. Results: WTP was significantly affected by women's opinion of the new medication, the level of co-payment required, net household income, whether currently in treatment for menopausal symptoms, and Menopause Rating Scale (MRS) values. Compared with other factors, the level of co-payment was predicted to have a negative impact on WTP. Income level is an important factor in WTP and correlates highly with several other health-related variables (WHO-5 index, MRS value, receipt of other menopause medicines and existing co-morbidity). The average co-payment that our group of women was willing to pay was between is an element of 17 and is an element of 35 per month, or is an element of 24 to is an element of 42 for women who were currently receiving treatment for symptorns of menopause. While interpreting the results, it should be considered that the hypothetical therapy was assumed to be a new non-reimbursable alternative to conventional therapy offered under the existing statutory framework for health insurance in Germany. Conclusions: Despite some methodological limitations, these results are useful for examining the factors affecting WTP and incremental utilities for future medicine dealing with menopause.
Erscheinungsjahr
2009
Zeitschriftentitel
PHARMACOECONOMICS
Band
27
Ausgabe
8
Seite(n)
693-704
ISSN
1170-7690
Page URI
https://pub.uni-bielefeld.de/record/1590239
Zitieren
Rasch A, Hodek J-M, Runge C, Greiner W. Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS. 2009;27(8):693-704.
Rasch, A., Hodek, J. - M., Runge, C., & Greiner, W. (2009). Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS, 27(8), 693-704. https://doi.org/10.2165/11312740-000000000-00000
Rasch, Andrej, Hodek, Jan-Marc, Runge, Claus, and Greiner, Wolfgang. 2009. “Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women”. PHARMACOECONOMICS 27 (8): 693-704.
Rasch, A., Hodek, J. - M., Runge, C., and Greiner, W. (2009). Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS 27, 693-704.
Rasch, A., et al., 2009. Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS, 27(8), p 693-704.
A. Rasch, et al., “Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women”, PHARMACOECONOMICS, vol. 27, 2009, pp. 693-704.
Rasch, A., Hodek, J.-M., Runge, C., Greiner, W.: Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women. PHARMACOECONOMICS. 27, 693-704 (2009).
Rasch, Andrej, Hodek, Jan-Marc, Runge, Claus, and Greiner, Wolfgang. “Determinants of Willingness to Pay for a New Therapy in a Sample of Menopausal-Aged Women”. PHARMACOECONOMICS 27.8 (2009): 693-704.
Daten bereitgestellt von European Bioinformatics Institute (EBI)
2 Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.
Mattsson LÅ, Ericsson Å, Bøgelund M, Maamari R., Maturitas 74(3), 2013
PMID: 23312488
Mattsson LÅ, Ericsson Å, Bøgelund M, Maamari R., Maturitas 74(3), 2013
PMID: 23312488
Willingness to pay for hospice care using the contingent valuation method.
Kim MO, Lee KS, Kim JH, Joo JS., Yonsei Med J 52(3), 2011
PMID: 21488196
Kim MO, Lee KS, Kim JH, Joo JS., Yonsei Med J 52(3), 2011
PMID: 21488196
44 References
Daten bereitgestellt von Europe PubMed Central.
Drummond, 2005
Arrow, Federal Register 58(10), 1993
Portney, J Econ Perspect 8(4), 1994
Use of contingent valuation to place a monetary value on pharmacy services: an overview and review of the literature.
Blumenschein K, Johannesson M., Clin Ther 21(8), 1999
PMID: 10485511
Blumenschein K, Johannesson M., Clin Ther 21(8), 1999
PMID: 10485511
Willingness to pay for antihypertensive therapy--further results.
Johannesson M, Johansson PO, Kristrom B, Gerdtham UG., J Health Econ 12(1), 1993
PMID: 10126492
Johannesson M, Johansson PO, Kristrom B, Gerdtham UG., J Health Econ 12(1), 1993
PMID: 10126492
Willingness to pay for sensory attributes of intranasal corticosteroids among patients with allergic rhinitis.
Mahadevia P, Shah S, Mannix S, Brewster-Jordan J, Kleinman L, Liebman C, O'Dowd L., J Manag Care Pharm 12(2), 2006
PMID: 16515372
Mahadevia P, Shah S, Mannix S, Brewster-Jordan J, Kleinman L, Liebman C, O'Dowd L., J Manag Care Pharm 12(2), 2006
PMID: 16515372
Willingness to pay to assess patient preferences for therapy in a Canadian setting.
Marra CA, Frighetto L, Goodfellow AF, Wai AO, Chase ML, Nicol RE, Leong CA, Tomlinson S, Ferreira BM, Jewesson PJ., BMC Health Serv Res 5(), 2005
PMID: 15941474
Marra CA, Frighetto L, Goodfellow AF, Wai AO, Chase ML, Nicol RE, Leong CA, Tomlinson S, Ferreira BM, Jewesson PJ., BMC Health Serv Res 5(), 2005
PMID: 15941474
Willingness to pay for depression treatment in primary care.
Unutzer J, Katon WJ, Russo J, Simon G, von Korff M, Lin E, Walker E, Ludman E, Bush T., Psychiatr Serv 54(3), 2003
PMID: 12610241
Unutzer J, Katon WJ, Russo J, Simon G, von Korff M, Lin E, Walker E, Ludman E, Bush T., Psychiatr Serv 54(3), 2003
PMID: 12610241
Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma.
Weston A, Fitzgerald P., Pharmacoeconomics 22(18), 2004
PMID: 15606226
Weston A, Fitzgerald P., Pharmacoeconomics 22(18), 2004
PMID: 15606226
Benefit evaluation of mass screening for prostate cancer: willingness-to-pay measurement using contingent valuation.
Yasunaga H, Ide H, Imamura T, Ohe K., Urology 68(5), 2006
PMID: 17113896
Yasunaga H, Ide H, Imamura T, Ohe K., Urology 68(5), 2006
PMID: 17113896
A utility-theoretic approach to the aggregation of willingness to pay measured in decomposed scenarios: development and empirical test.
Hammerschmidt T, Zeitler HP, Leidl R., Health Econ 13(4), 2004
PMID: 15067672
Hammerschmidt T, Zeitler HP, Leidl R., Health Econ 13(4), 2004
PMID: 15067672
Patients' willingness to pay for anti-emetic treatment.
Kerger H, Turan A, Kredel M, Stuckert U, Alsip N, Gan TJ, Apfel CC., Acta Anaesthesiol Scand 51(1), 2007
PMID: 17229228
Kerger H, Turan A, Kredel M, Stuckert U, Alsip N, Gan TJ, Apfel CC., Acta Anaesthesiol Scand 51(1), 2007
PMID: 17229228
Patient willingness to pay for preventive measures in primary care: a study of five GPs in a German community.
Wiesemann A, Mueller-Buehl U, Scheidt R, Boehme W, Scheuermann W., Soz Praventivmed 49(4), 2004
PMID: 15357527
Wiesemann A, Mueller-Buehl U, Scheidt R, Boehme W, Scheuermann W., Soz Praventivmed 49(4), 2004
PMID: 15357527
Schöffski, 2007
The discrete-choice willingness-to-pay question format in health economics: should we adopt environmental guidelines?
Smith RD., Med Decis Making 20(2), 2000
PMID: 10772357
Smith RD., Med Decis Making 20(2), 2000
PMID: 10772357
Health care contingent valuation studies: a review and classification of the literature.
Diener A, O'Brien B, Gafni A., Health Econ 7(4), 1998
PMID: 9683092
Diener A, O'Brien B, Gafni A., Health Econ 7(4), 1998
PMID: 9683092
Warm glow, free-riding and vehicle neutrality in a health-related contingent valuation study.
Hackl F, Pruckner GJ., Health Econ 14(3), 2005
PMID: 15386649
Hackl F, Pruckner GJ., Health Econ 14(3), 2005
PMID: 15386649
Empirical implications of response acquiescence in discrete-choice contingent valuation.
Yeung RY, Smith RD, Ho LM, Johnston JM, Leung GM., Health Econ 15(10), 2006
PMID: 16518835
Yeung RY, Smith RD, Ho LM, Johnston JM, Leung GM., Health Econ 15(10), 2006
PMID: 16518835
Schneider, 2006
Milsom, 2006
A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century.
Rodstrom K, Bengtsson C, Lissner L, Milsom I, Sundh V, Bjorkelund C., Menopause 9(3), 2002
PMID: 11973438
Rodstrom K, Bengtsson C, Lissner L, Milsom I, Sundh V, Bjorkelund C., Menopause 9(3), 2002
PMID: 11973438
Treatment of menopausal symptoms: what shall we do now?
Hickey M, Davis SR, Sturdee DW., Lancet 366(9483), 2005
PMID: 16054942
Hickey M, Davis SR, Sturdee DW., Lancet 366(9483), 2005
PMID: 16054942
Measuring the impact of menopausal symptoms on quality of life.
Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M., BMJ 307(6908), 1993
PMID: 8401125
Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M., BMJ 307(6908), 1993
PMID: 8401125
AUTHOR UNKNOWN, Menopause 7(1), 2007
Eberhardt, GMS Health Technol Assess 3(Doc03), 2007
Decision makers' and scientists' opinion about contingent valuation and choice experiments for measuring willingness to pay in health care: results from a survey in Germany.
Gunther OH, Konig HH., Int J Technol Assess Health Care 22(3), 2006
PMID: 16984064
Gunther OH, Konig HH., Int J Technol Assess Health Care 22(3), 2006
PMID: 16984064
Rote, 2008
Potthoff, German Medical Science 02(Doc05), 2004
The Menopause Rating Scale (MRS) scale: a methodological review.
Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT., Health Qual Life Outcomes 2(), 2004
PMID: 15345062
Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT., Health Qual Life Outcomes 2(), 2004
PMID: 15345062
The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study.
Heinemann LA, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HP., Health Qual Life Outcomes 2(), 2004
PMID: 15555079
Heinemann LA, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HP., Health Qual Life Outcomes 2(), 2004
PMID: 15555079
The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36.
Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM., Climacteric 3(1), 2000
PMID: 11910610
Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM., Climacteric 3(1), 2000
PMID: 11910610
Literature review of instruments to assess health-related quality of life during and after menopause.
Zollner YF, Acquadro C, Schaefer M., Qual Life Res 14(2), 2005
PMID: 15892422
Zollner YF, Acquadro C, Schaefer M., Qual Life Res 14(2), 2005
PMID: 15892422
Validity of the five-item WHO Well-Being Index (WHO-5) in an elderly population.
Bonsignore M, Barkow K, Jessen F, Heun R., Eur Arch Psychiatry Clin Neurosci 251 Suppl 2(), 2001
PMID: 11824831
Bonsignore M, Barkow K, Jessen F, Heun R., Eur Arch Psychiatry Clin Neurosci 251 Suppl 2(), 2001
PMID: 11824831
The WHO-5 Wellbeing Index performed the best in screening for depression in primary care.
Primack BA., ACP J. Club 139(2), 2003
PMID: 12954040
Primack BA., ACP J. Club 139(2), 2003
PMID: 12954040
Donaldson, Appl Econ 30(), 1998
Field, 2005
The impact of hormone replacement therapy on quality of life and willingness to pay.
Zethraeus N, Johannesson M, Henriksson P, Strand RT., Br J Obstet Gynaecol 104(10), 1997
PMID: 9332999
Zethraeus N, Johannesson M, Henriksson P, Strand RT., Br J Obstet Gynaecol 104(10), 1997
PMID: 9332999
Willingness to pay for hormone replacement therapy.
Zethraeus N., Health Econ 7(1), 1998
PMID: 9541082
Zethraeus N., Health Econ 7(1), 1998
PMID: 9541082
Patients' willingness to pay for pharmacist-provided menopause and hormone replacement therapy consultations.
Barner JC, Branvold A., Res Social Adm Pharm 1(1), 2005
PMID: 17138467
Barner JC, Branvold A., Res Social Adm Pharm 1(1), 2005
PMID: 17138467
The impact of hormone replacement therapy on quality of life and willingness to pay.
Morris EP., Br J Obstet Gynaecol 106(6), 1999
PMID: 10426631
Morris EP., Br J Obstet Gynaecol 106(6), 1999
PMID: 10426631
Willingness to pay for antihypertensive care: evidence from a staff-model HMO.
Ramsey SD, Sullivan SD, Psaty BM, Patrick DL., Soc Sci Med 44(12), 1997
PMID: 9194252
Ramsey SD, Sullivan SD, Psaty BM, Patrick DL., Soc Sci Med 44(12), 1997
PMID: 9194252
Age at menopause as a risk factor for cardiovascular mortality.
van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD., Lancet 347(9003), 1996
PMID: 8602000
van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD., Lancet 347(9003), 1996
PMID: 8602000
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 19712011
PubMed | Europe PMC
Suchen in